Radiation	0	9	O
retinopathy	10	21	O
is	22	24	O
treatable	25	34	O
with	35	39	O
anti	40	44	O
-	44	45	O
vascular	45	53	B-Gene_or_gene_product
endothelial	54	65	I-Gene_or_gene_product
growth	66	72	I-Gene_or_gene_product
factor	73	79	I-Gene_or_gene_product
bevacizumab	80	91	B-Drug_or_compound
(	92	93	O
Avastin	93	100	B-Drug_or_compound
)	100	101	O
.	101	102	O

PURPOSE	104	111	O
:	111	112	O
To	113	115	O
report	116	122	O
on	123	125	O
bevacizumab	126	137	B-Drug_or_compound
treatment	138	147	O
for	148	151	O
radiation	152	161	O
retinopathy	162	173	O
affecting	174	183	O
the	184	187	O
macula	188	194	B-Tissue
.	194	195	O

PATIENTS	196	204	O
AND	205	208	O
METHODS	209	216	O
:	216	217	O
Twenty	218	224	O
-	224	225	O
one	225	228	O
patients	229	237	B-Organism
with	238	242	O
radiation	243	252	O
retinopathy	253	264	O
(	265	266	O
edema	266	271	B-Pathological_formation
,	271	272	O
hemorrhages	273	284	O
,	284	285	O
capillary	286	295	B-Tissue
dropout	296	303	O
,	303	304	O
and	305	308	O
neovascularization	309	327	O
)	327	328	O
and	329	332	O
a	333	334	O
subjective	335	345	O
or	346	348	O
objective	349	358	O
loss	359	363	O
of	364	366	O
vision	367	373	O
were	374	378	O
treated	379	386	O
.	386	387	O

Treatment	388	397	O
involved	398	406	O
intravitreal	407	419	O
injection	420	429	O
of	430	432	O
bevacizumab	433	444	B-Drug_or_compound
(	445	446	O
1	446	447	O
.	447	448	O
25	448	450	O
mg	451	453	O
in	454	456	O
0	457	458	O
.	458	459	O
05	459	461	O
mL	462	464	O
)	464	465	O
every	466	471	O
6	472	473	O
-	473	474	O
12	474	476	O
weeks	477	482	O
.	482	483	O

Treatment	484	493	O
was	494	497	O
discontinued	498	510	O
at	511	513	O
patient	514	521	B-Organism
request	522	529	O
or	530	532	O
if	533	535	O
there	536	541	O
was	542	545	O
no	546	548	O
measurable	549	559	O
response	560	568	O
to	569	571	O
therapy	572	579	O
.	579	580	O

Main	581	585	O
outcome	586	593	O
measures	594	602	O
included	603	611	O
best	612	616	O
corrected	617	626	O
visual	627	633	O
acuity	634	640	O
,	640	641	O
ophthalmic	642	652	O
examination	653	664	O
,	664	665	O
retinal	666	673	O
photography	674	685	O
,	685	686	O
and	687	690	O
angiography	691	702	O
.	702	703	O

RESULTS	704	711	O
:	711	712	O
Bevacizumab	713	724	B-Drug_or_compound
treatment	725	734	O
was	735	738	O
followed	739	747	O
by	748	750	O
reductions	751	761	O
in	762	764	O
retinal	765	772	O
hemorrhage	773	783	O
,	783	784	O
exudation	785	794	O
,	794	795	O
and	796	799	O
edema	800	805	B-Pathological_formation
.	805	806	O

Visual	807	813	O
acuities	814	822	O
were	823	827	O
stable	828	834	O
or	835	837	O
improved	838	846	O
in	847	849	O
86	850	852	O
%	852	853	O
(	854	855	O
n	855	856	O
=	856	857	O
18	857	859	O
)	859	860	O
.	860	861	O

Three	862	867	O
patients	868	876	B-Organism
discontinued	877	889	O
therapy	890	897	O
.	897	898	O

Each	899	903	O
was	904	907	O
legally	908	915	O
blind	916	921	O
before	922	928	O
treatment	929	938	O
(	939	940	O
n	940	941	O
=	941	942	O
1	942	943	O
)	943	944	O
,	944	945	O
experienced	946	957	O
little	958	964	O
to	965	967	O
no	968	970	O
subjective	971	981	O
improvement	982	993	O
(	994	995	O
n	995	996	O
=	996	997	O
2	997	998	O
)	998	999	O
,	999	1000	O
or	1001	1003	O
was	1004	1007	O
poorly	1008	1014	O
compliant	1015	1024	O
(	1025	1026	O
n	1026	1027	O
=	1027	1028	O
2	1028	1029	O
)	1029	1030	O
.	1030	1031	O

Three	1032	1037	O
patients	1038	1046	B-Organism
(	1047	1048	O
14	1048	1050	O
%	1050	1051	O
)	1051	1052	O
regained	1053	1061	O
2	1062	1063	O
or	1064	1066	O
more	1067	1071	O
lines	1072	1077	O
of	1078	1080	O
visual	1081	1087	O
acuity	1088	1094	O
.	1094	1095	O

No	1096	1098	O
ocular	1099	1105	O
or	1106	1108	O
systemic	1109	1117	O
bevacizumab	1118	1129	B-Drug_or_compound
-	1129	1130	O
related	1130	1137	O
side	1138	1142	O
effects	1143	1150	O
were	1151	1155	O
observed	1156	1164	O
.	1164	1165	O

CONCLUSIONS	1166	1177	O
:	1177	1178	O
Intravitreal	1179	1191	O
bevacizumab	1192	1203	B-Drug_or_compound
can	1204	1207	O
be	1208	1210	O
used	1211	1215	O
to	1216	1218	O
treat	1219	1224	O
radiation	1225	1234	O
retinopathy	1235	1246	O
.	1246	1247	O

In	1248	1250	O
most	1251	1255	O
cases	1256	1261	O
treatment	1262	1271	O
was	1272	1275	O
associated	1276	1286	O
with	1287	1291	O
decreased	1292	1301	O
vascular	1302	1310	B-Multi-tissue_structure
leakage	1311	1318	O
,	1318	1319	O
stabilization	1320	1333	O
,	1333	1334	O
or	1335	1337	O
improved	1338	1346	O
vision	1347	1353	O
.	1353	1354	O

An	1355	1357	O
anti	1358	1362	O
-	1362	1363	O
vascular	1363	1371	B-Gene_or_gene_product
endothelial	1372	1383	I-Gene_or_gene_product
growth	1384	1390	I-Gene_or_gene_product
factor	1391	1397	I-Gene_or_gene_product
strategy	1398	1406	O
may	1407	1410	O
reduce	1411	1417	O
tissue	1418	1424	B-Tissue
damage	1425	1431	O
associated	1432	1442	O
with	1443	1447	O
radiation	1448	1457	O
vasculopathy	1458	1470	O
and	1471	1474	O
neuropathy	1475	1485	O
.	1485	1486	O

